

(19) World Intellectual Property Organization International Bureau



. I (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11) (1,11)

(43) International Publication Date 5 February 2004 (05.02.2004)

PCT

(10) International Publication Number WO 2004/011622 A3

(51) International Patent Classification7: C12N 5/06, 5/08

(21) International Application Number:

PCT/US2003/023869

(22) International Filing Date: 30 July 2003 (30.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/399,493

30 July 2002 (30.07.2002) US

(71) Applicant (for all designated States except US): MASS-ACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02173 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEACH, John, K. [US/US]; 328 Commercial Street #22. Boston, MA 02109 (US). TANNENBAUM, Steven, R. [US/US]; 15 Bent Hill Drive, Framingham, MA 01701 (US).

(74) Agents: EISENSTEIN, Ronald, I. et al.; Nixon Peabody LLP, 100 Summer Street, Boston, MA 02110-2131 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH. GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 26 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR PERFUSION AND PLATING OF PRIMARY HEPATOCYTES AND A MEDIUM THEREFORE

(57) Abstract: The present invention provides methods for culturing primary hepatocytes with improved long term function and improved viability, by plating the hepatocytes in the presence of an anti-oxidants) as well as an agent(s) which is a functional inhibitor of enzymes that generate reactive oxygen and reactive nitrogen species. One preferred embodiment provides a combination of 2-oxothizolidine and tocopherol succinate. Another preferred embodiment provides a combination of N^{tr}-methylarginine and mannitol.

To: RONALD I. EISENSTEIN NIXON PEABODY LLP 101 FEDERAL STREET BOSTON, MA 02110	PCT NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION (PCT Rule 44.1) Date of Mailing (day/month/year) 06 JUL 2004
Applicant's or agent's file reference 019028-05287	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US03/23869	International filing date (day/month/year) 30 July 2003 (30.07.2003)
Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY	
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the cla When? The time limit for filing such amendments is international search report. Where? Directly to the International Bureau of WIPC 1211 Geneva 20, Switzerland, Facsimile No.	normally two months from the date of transmittal of the 0, 34, chemin des Colombettes :: (41-22) 740.14.35
For more detailed instructions, see the notes on the a	
2. The applicant is hereby notified that no international search Article 17(2)(a) to that effect is transmitted herewith.	
-	ional fee(s) under Rule 40.2, the applicant is notified that:
applicant's request to forward the texts of both the p	en transmitted to the International Bureau together with the protest and the decision thereon to the designated Offices.
_	plicant will be notified as soon as a decision is made.
4. Reminders	nal application will be published by the International Bureau. If the
applicant wishes to avoid or postpone publication, a notice of with	hdrawal of the international application, or of the priority claim, must

reach the International Bureau as provided in Rules 90 bis.1 and 90 bis.3, respectively, before the comple preparations for international publication.

Within 19 months from the priority date, but only in respect of some designated Offices, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later); otherwise the applicant must, within 20 months from the priority date, perform the prescribed acts for entry into the national phase before those designated Offices.

In respect of other designated Offices, the time limit of 30 months (or later) will apply even if no demand is filed within 19 months.

See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Telephone No. 571/272-1600

(See notes on accompanying sheet)

PCT


INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 019028-05287	FOR FURTHER ACTION		cation of Transmittal of International Search Report T/ISA/220) as well as, where applicable, item 5
International application No. PCT/US03/23869	International filing date (day/moi 30 July 2003 (30.07.2003)	nth/year)	(Earliest) Priority Date (day/month/year) 30 July 2002 (30.07.2002)
Applicant MASSACHUSETTS INSTITUTE OF 1	TECHNOLOGY		
This international search report has be applicant according to Article 18. A	een prepared by this International Scopy is being transmitted to the Int	Searching A	Authority and is transmitted to the Bureau.
This international search report consist It is also accompani	ets of a total of $\frac{1}{2}$ sheets.	ıment cite	d in this report.
	e, the international search was carrie ed, unless otherwise indicated under		e basis of the international application in the
Authority (Rule 23.1(b)). b. With regard to any nucleoti			ne international application furnished to this
contained in the internation	onal application in written form.		·
filed together with the inte	ernational application in computer re	adable for	m.
furnished subsequently to	this Authority in written form.		
furnished subsequently to	this Authority in computer readable	form.	·
the statement that the subsinternational application a		listing doe	es not go beyond the disclosure in the
the statement that the info	rmation recorded in computer readal	ole form is	identical to the written sequence listing has
2. Certain claims were four	nd unsearchable (See Box I).		
3. Unity of invention is lack	ing (See Box II).		
4. With regard to the title,	to the decree		·
the text is approved as sub	• • • • • • • • • • • • • • • • • • • •		
the text has been establish	ed by this Authority to read as follow	<i>N</i> S:	
5. With regard to the abstract,			
the text is approved as sub	mitted by the applicant.		
the text has been established			y as it appears in Box III. The applicant ch report, submit comments to this
6. The figure of the drawings to be p	ublished with the abstract is Figure	No	
as suggested by the applica	nt.		None of the figures
because the applicant failed	d to suggest a figure.		
because this figure better c	haracterizes the invention.		

Form PCT/ISA/210 (first sheet) (July 1998)





International application No.

PCT/US03/23869

IPC(7) US CL	SSIFICATION OF SUBJECT MATTER : C12N 5/06, 5/08 : 435/383, 366		
	o International Patent Classification (IPC) or to both LDS SEARCHED	national classification and IPC	
Minimum do	ocumentation searched (classification system followe 435/383, 366	d by classification symbols)	
Documentati	ion searched other than minimum documentation to t	he extent that such documents are included	in the fields searched
	ata base consulted during the international search (na continuation Sheet	ame of data base and, where practicable, s	earch terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where a	appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,198,432 A(FARISS) 30 March 1993 (30.03.	1993), column 13, lines 10-25.	1-8
Y	ROBERTS et al. Prodrugs of L-Cysteine as Protec Induced Hepatotoxicuty. 2-(Polyhydroxyalkyl)-and carboxylic Acids. Journal of Medicinal Chemistry. 1896, especially abstract.	l 2-(Polyhydroxyalkyl)thiazolidine-4(r)-	1-8
Y	DILWORTH et al. Spntaneous Nitric Oxide in Her Compound-Induced Apoptosis. Toxicology in Vitro pages 623-630, especialy abstact.		1-8
Y	POURAHMAD et al. A Comparison of Hepatocyte Cd2+. Toxicology. March 2000, Vol 143, No. 3,		1-8
Further	documents are listed in the continuation of Box C.	See patent family annex.	
* Sp	secial categories of cited documents:	"T" later document published after the inter date and not in conflict with the applica	ation but cited to understand the
	defining the general state of the art which is not considered to be ar relevance	principle or theory underlying the inve	
"E" earlier app	olication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone	ed to involve an inventive step
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the of considered to involve an inventive step combined with one or more other such	when the document is
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	art
"P" document priority da	published prior to the international filing date but later than the te claimed	"&" document member of the same patent f	amily
Date of the ac	tual completion of the international search	Date of mailing of the international sear	
19 March 200	4 (19.03.2004)	06	JUL ZULA
Name and ma Mail	illing address of the ISA/US Stop PCT, Atm: ISA/US missioner for Patents	Authorized officer Bell	JUL 2004 barrisga
Alex	Box 1450 andria, Virginia 22313-1450 (703)305-3230	Telephone No. 571/272-1600	U



PCT/US.	3869		

		•	
	·		
an amazine cranet	TED 14 2.		
Continuation of B. FIELDS SEARCH WEST USPT, DWPI; STN: BIOSIS, CAP searcg terms: hepatocytes, anti-oxidant, to	LUS, MEDLINE copherol succinate, mannitol,	nitric oxide, methylaraginine	, oxo-thiazolidine
semeg terms, reputer, and the sement	, , , , , , , , , , , , , , , , , , ,		
	_		
	<u>-</u>		
	-		
	-		
	-		
	-		
	-		
	-		
	-		
	-		
	-		
	_		
,	-		
	-		
	_		
	_		
	-		
	-		





NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- 1. [Where originally there were 48 claims and after amendment of some claims there are 51]: "Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
 "Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
 "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- 4. [Where various kinds of amendments are made]: "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under Article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see the PCT Applicant's Guide, Volume II.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/23869

	SSIFICATION OF SUBJECT MATTER		i
IPC(7) US CL	: C12N 5/06, 5/08 : 435/383, 366		
	International Patent Classification (IPC) or to both	national classification and IPC	
B. FIEI	DS SEARCHED		
	ocumentation searched (classification system follower 435/383, 366	1 by classification symbols)	
Documentat	ion searched other than minimum documentation to the	ne extent that such documents are included	in the fields searched
	ata base consulted during the international search (na continuation Sheet	me of data base and, where practicable, s	earch terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where a		Relevant to claim No.
Y	US 5,198,432 A(FARISS) 30 March 1993 (30.03.1	1993), column 13, lines 10-25.	1-8
Y	ROBERTS et al. Prodrugs of L-Cysteine as Protec Induced Hepatotoxicuty. 2-(Polyhydroxyalkyl)-and carboxylic Acids. Journal of Medicinal Chemistry. 1896, especially abstract.	2-(Polyhydroxyalkyl)thiazolidine-4(r)-	1-8
Y -	DILWORTH et al. Spntaneous Nitric Oxide in Heq Compound-Induced Apoptosis. Toxicology in Vitro pages 623-630, especialy abstact.		1-8
Y	POURAHMAD et al. A Comparison of Hepatocyte Cd2+. Toxicology. March 2000, Vol 143, No. 3,		1-8
Further	documents are listed in the continuation of Box C.	See patent family annex.	
* S	pecial categories of cited documents:	"T" later document published after the inter	
	defining the general state of the art which is not considered to be alar relevance	date and not in conflict with the application principle or theory underlying the investment of a solution and applications.	ntion
•	plication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone	
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	
priority d	published prior to the international filing date but later than the ate claimed	"&" document member of the same patent f	
	ctual completion of the international search	Date of mailing of the international sear	JUL 2004
	04 (19.03.2004) ailing address of the ISA/US	Authorized officer O	//
Mai Con	I Stop PCT, Attn: ISA/US nmissioner for Patents . Box 1450		JUL 2004 berrisga
Alex	candria, Virginia 22313-1450 c. (703)305-3230	Telephone No. 571/272-1600	U

Form PCT/ISA/210 (second sheet) (July 1998)

	PCT/US03/23869
INTERNATIONAL SEARCH REPORT	
HANDER WALLOW DESIGNATION AND DESIGNATION OF THE PARTY OF	
•	
•	
	ı
•	
Continuation of B. FIELDS SEARCHED Item 3:	
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant,	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, mannito	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
WEST USPT, DWPI; STN: BIOSIS, CAPLUS, MEDLINE searcg terms: hepatocytes, anti-oxidant, tocopherol succinate, mannitol, nitric oxidant, man	xide, methylaraginine, oxo-thiazolidine
	xide, methylaraginine, oxo-thiazolidine

Form PCT/ISA/210 (second sheet) (July 1998)